htx-019
Total Payments
$178,489
Transactions
9
Doctors
0
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2020 | $178,489 | 9 | 0 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $178,489 | 9 | 100.0% |
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1) | Heron Therapeutics, Inc. | $178,489 | 0 |
Top Doctors Receiving Payments for htx-019
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Orange, CA | $178,489 | 9 |
Ad
Manufacturing Companies
- Heron Therapeutics, Inc. $178,489
Product Information
- Type Drug
- Total Payments $178,489
- Total Doctors 0
- Transactions 9
About htx-019
htx-019 is a drug associated with $178,489 in payments to 0 healthcare providers, recorded across 9 transactions in the CMS Open Payments database. The primary manufacturer is Heron Therapeutics, Inc..
Payment data is available from 2020 to 2020. In 2020, $178,489 was paid across 9 transactions to 0 doctors.
The most common payment nature for htx-019 is "Unspecified" ($178,489, 100.0% of total).
htx-019 is associated with 1 research study, including "Aprepitant Injectable Emulsion in Patients With COVID-19 (GUARDS-1)" ($178,489).